Skip to main content

Advertisement

Log in

Rapid blood cell recovery with immunosuppressive therapy combined with romiplostim in a patient with very severe hepatitis-associated aplastic anemia who underwent liver transplantation

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Patients with hepatitis-associated aplastic anemia (HAA) who undergo living-donor liver transplantation (LDLT) have a poor prognosis with infections and bleeding complications. Rapid recovery of blood cells is critical for preventing these complications and improving the outcome. Immunosuppressive therapy (IST) combined with thrombopoietin receptor agonists is considered effective for aplastic anemia. However, there are no data on the benefits of adding thrombopoietin receptor agonists to IST for HAA. We present the case of a child with severe HAA who underwent LDLT, and who achieved rapid blood cell recovery with IST combined with romiplostim, a thrombopoietin receptor agonist. In addition, despite having undergone LDLT, the patient had no adverse events such as serious liver dysfunction or thrombosis. This case suggests that IST combined with thrombopoietin receptor agonists may be a promising treatment option for HAA patients undergoing LDLT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Alshaibani A, Dufour C, Risitano A, de Latour R, Aljurf M. Hepatitis-associated aplastic anemia. Hematol Oncol Stem Cell Ther. 2020. https://doi.org/10.1016/j.hemonc.2020.10.001 (Online ahead of print).

    Article  PubMed  Google Scholar 

  2. De Bruyne RM, Dhawan A. Bone marrow dysfunction following pediatric liver transplantation. Pediatr Transplant. 2005;9:423–6.

    Article  Google Scholar 

  3. Young NS. Aplastic anemia. N Engl J Med. 2018;379:1643–56.

    Article  CAS  Google Scholar 

  4. Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376:1540–50.

    Article  CAS  Google Scholar 

  5. Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rappeport JM, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53:504–14.

    Article  CAS  Google Scholar 

  6. Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049–54.

    Article  CAS  Google Scholar 

  7. Delehaye F, Habes D, Dourthe ME, Bertrand Y, Michel G, Gaudichon J, et al. Management of childhood aplastic anemia following liver transplantation for nonviral hepatitis: a french survey. Pediatr Blood Cancer. 2020;67:28177.

    Article  Google Scholar 

  8. Osugi Y, Yagasaki H, Sako M, Kosaka Y, Taga T, Ito T, et al. Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplastic anemia. Haematologica. 2007;92:1687–90.

    Article  CAS  Google Scholar 

  9. Mohseny AB, Eikema DA, Neven B, Kröger N, Shaw PJ, Damaj G, et al. Hematopoietic stem cell transplantation for hepatitis-associated aplastic anemia following liver transplantation for nonviral hepatitis: a retrospective analysis and a review of the literature by the severe aplastic anemia working party of the european society for blood and marrow transplantation (SAAWP-EBMT). J Pediatr Hematol Oncol. 2020. https://doi.org/10.1097/MPH.0000000000001991.

    Article  PubMed  Google Scholar 

  10. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144:206–16.

    Article  CAS  Google Scholar 

  11. Fuhrer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106:2102–4.

    Article  Google Scholar 

  12. Chang MH, Kim KH, Kim HS, Jun HJ, Kim DH, Jang JH, et al. Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. Eur J Haematol. 2010;84:154–9.

    Article  CAS  Google Scholar 

  13. Locasciulli A, Bacigalupo A, Bruno B, Montante B, Marsh J, Tichelli A, et al. Hepatitis-associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party. Br J Haematol. 2010;149:890–5.

    Article  Google Scholar 

  14. Dultz G, Kronenberger B, Azizi A, Mihm U, Vogl TJ, Sarrazin U, et al. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. J Hepatol. 2011;55:229–32.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

HY, YK, YS, and AM wrote the manuscript. YK, HN, YO, YH, NO, YS, YO, YS, and A.M. provided medical care for the patient. All authors commented on the manuscript and contributed to the final manuscript.

Corresponding author

Correspondence to Yuta Kawahara.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest in association with the present study.

Informed consent

Written informed consent for the off-label use of romiplostim was obtained from the parents.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshinari, H., Kawahara, Y., Niijima, H. et al. Rapid blood cell recovery with immunosuppressive therapy combined with romiplostim in a patient with very severe hepatitis-associated aplastic anemia who underwent liver transplantation. Int J Hematol 114, 524–527 (2021). https://doi.org/10.1007/s12185-021-03165-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-021-03165-z

Keywords

Navigation